A single center, randomized, blind, in parallel clinical study to compare pharmacokinetics profile of testing drug to originator, with a single dose of Recombinant Human HER2 Monoclonal Anitbody for Injection in healthy volunteers.
Latest Information Update: 16 Feb 2021
At a glance
- Drugs Recombinant human HER2 monoclonal antibody Anhui Anke Biotechnology (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- 01 Jul 2020 Status changed to completed, results published in the Expert Opinion on Investigational Drugs
- 16 Nov 2016 New trial record